This site is intended for Healthcare professionals only.
medical dialogues

Lupin gets FDA approval for Hydrocodone Bitartrate and Acetaminophen Tablets

Lupin gets FDA approval for Hydrocodone Bitartrate and Acetaminophen Tablets

Mumbai  :  Pharma major, Lupin Limited, announced that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg from the United  States  Food and Drug Administration (FDA) to market a generic equivalent of Mikart, Inc’s Hydrocodone  Bitartrate  and Acetaminophen  Tablets  USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg.

Lupin’s Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg are the AA rated generic equivalent of Mikart, Inc’s Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg. It is indicated for the relief of moderate to moderately severe pain.

Hydrocodone Bitartrate and Acetaminophen Tablets USP had US sales of $ 89.6 million (IMS MAT September 2016).

Stock View:

Lupin Ltd is currently trading at Rs 1430, up by Rs 22.45 or 1.59% from its previous closing of Rs 1407.55 on the BSE.

The scrip opened at Rs 1412 and has touched a high and low of Rs 1437.7 and Rs 1405 respectively. So far 594846(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 63514.71 crore.

The BSE group ‘A’ stock of face value Rs 2 has touched a 52 week high of Rs 1911.55 on 09-Feb-2016 and a 52 week low of Rs 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs 1548.8 and Rs 1393 respectively.

The promoters holding in the company stood at 46.74% while Institutions and Non-Institutions held 41.85% and 11.41% respectively.

The stock is currently trading below its 200 DMA.

Source: Press Release
0 comment(s) on Lupin gets FDA approval for Hydrocodone Bitartrate and Acetaminophen Tablets

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted